|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Population Medicine and
Diagnostic Sciences and the Department of Molecular Medicine, College
of Veterinary Medicine, Cornell University, Ithaca, NY.
We have discovered a novel canine hereditary bleeding disorder with
the characteristic features of Scott syndrome, a rare defect of
platelet procoagulant activity. Affected dogs were from a single,
inbred colony and experienced clinical signs of epistaxis, hyphema,
intramuscular hematoma, and prolonged bleeding with cutaneous bruising
after surgery. The hemostatic abnormalities identified were restricted
to tests of platelet procoagulant activity, whereas platelet count,
platelet morphology under light microscopy, bleeding time, clot
retraction, and platelet aggregation and secretion in response to
thrombin, collagen, and adenosine diphosphate stimulation were all
within normal limits. Washed platelets from the affected dogs
demonstrated approximately twice normal clotting times in a platelet
factor 3 availability assay and, in a prothrombinase assay, generated
only background levels of thrombin in response to calcium ionophore,
thrombin, or combined thrombin plus collagen stimulation. While
platelet phospholipid content was normal, flow cytometric analyses
revealed diminished phosphatidylserine exposure and a failure of
microvesiculation in response to calcium ionophore, thrombin, and
collagen stimulation. Pedigree studies indicate a likely homozygous
recessive inheritance pattern of the defect. These findings confirm the
importance of platelet procoagulant activity for in vivo hemostasis and
provide a large animal model for studying agonist-induced signal
transduction, calcium mobilization, and effector pathways involved in
the late platelet response of transmembrane phospholipid movement and
membrane vesiculation.
(Blood. 2002;99:2434-2441) Platelets play a critical role in the initiation
and regulation of hemostasis. Vascular injury triggers a series of
platelet reactions culminating in platelet aggregation and formation of a localized primary hemostatic plug. In the course of activation, the
platelet outer membrane is transformed to a catalytic surface for
assembly of active coagulation complexes. The tenase complex, consisting of factors IXa and VIIIa, proteolytically activates factor
X. In a similar fashion, the prothrombinase complex, consisting of
factor Xa and its cofactor Va, catalyzes conversion of prothrombin to
thrombin. Activated platelets support tenase and prothrombinase assembly primarily through membrane surface exposure of a negatively charged phospholipid, phosphatidylserine (PS). In a temporally related
process, activated platelets shed small membrane particles, microvesicles, which also present surface PS. Thus, PS expression by
activated platelets and microvesicles is the source of platelet procoagulant activity.1-4
The specific receptors and signaling pathways required for platelet
procoagulant activity, and their relationship to the other receptor-mediated platelet responses of aggregation and secretion, are
now being investigated. In nonactivated platelets, the
aminophospholipids PS and phosphatidylethanolamine (PE) are essentially
restricted to the inner membrane leaflet while the outer leaflet
consists predominately of phosphatidylcholine (PC) and sphingomyelin
(SM).5,6 This membrane lipid asymmetry requires the action
of a Mg2+ and adenosine triphosphate (ATP)-dependent
aminophospholipid translocase, which transports PS and PE to the inner
membrane.7,8 The rapid loss of membrane asymmetry, with
movement of PS to the outer membrane leaflet, is mediated by a
Ca++-dependent phospholipid scramblase.9,10
Platelet membrane PS exposure and microvesicle release can be induced
in vitro through a variety of stimuli that cause sustained elevation in
platelet cytosolic ionized calcium concentration
([Ca++]i).11-13 It is
believed that high [Ca++]i activates
scramblase with concomitant inhibition of translocase, resulting in
rapid bidirectional movement of phospholipids and the appearance
of surface PS. Microvesiculation apparently depends on membrane PS
exposure but also requires protein tyrosine phosphatase and calpain
activation.14 The physiologic platelet agonists, collagen
and thrombin, are capable of inducing PS exposure and microvesiculation; however, the rate and extent of response vary greatly depending on reaction conditions.15-18
Studies of Scott syndrome, a rare bleeding disorder associated with
deficiency of platelet procoagulant activity, have been used to explore
the basis of membrane PS movement.19-22 Characteristics of
this syndrome include a moderate to severe bleeding tendency with
normal platelet aggregation and secretion response but defective membrane transbilayer movement of PS and abnormal
microvesiculation.4,23,24 Molecular analyses of the
candidate gene scramblase in a single family, and in lymphocytes
derived from the original patient, have not revealed the molecular
basis of Scott syndrome.25,26 We report here the
phenotypic characterization of a naturally occurring bleeding disorder
of dogs caused by a lack of platelet procoagulant activity. Clinically
affected dogs have normal platelet aggregation and secretion. Platelet
prothrombinase activity, however, is markedly reduced, and platelets
demonstrate impaired PS exposure and microvesiculation in response to
both physiologic agonists and calcium ionophore stimulation.
Experimental animals
Coagulation, von Willebrand factor, and fibrinolysis
assays
Plasma lipid analyses
Platelet function testing Platelet count and mean platelet volume were measured in ethylenediaminetetraacetic acid whole blood samples using an automated hematology analyzer (Advia 120, Bayer, Tarrytown, NY), and Wright-stained blood films were reviewed by a veterinary clinical pathologist to assess platelet morphology. We measured bleeding time after incision of the buccal mucosa with a template device (Surgicutt, Organon Teknika).33 Clot retraction was measured in saline-dilute blood combined with 1 U thrombin. Platelet-rich plasma (PRP) for aggregation and secretion studies was prepared by centrifuging whole blood collected into 3.8% citrate at 650g at room temperature for 3 separate 3-minute intervals. The resultant PRP was pooled and adjusted to a platelet count of 300 × 109/L (300 000/µL) with autologous platelet-poor plasma (PPP) obtained by centrifuging blood samples at 2200g for 15 minutes. The PRP was allowed to rest at room temperature for 30 minutes prior to use. Platelet aggregation studies were performed as previously described34 using a lumiaggregometer (Model 500 Ca, Chrono-log, Havertown, PA). Agonist-induced dense granule secretion was detected as luminescence (Chrono-lume reagent, Chrono-log) by monitoring ATP release under conditions that minimize potentiation of canine platelet aggregation.35 Aggregation and secretion studies were completed within 2 hours of PRP preparation.Platelet factor 3 availability We used a reported method for measuring kaolin-induced platelet factor 3 availability (PF3a).20 Briefly, recalcification time was determined for a mixture of kaolin-activated PPP and PRP. The PRP was prepared from whole blood collected in 3.2% sodium citrate (1 vol citrate: 9 vol blood) and adjusted to a platelet count of 300 × 109/L (300 000/µL) with autologous PPP. Substitution studies were performed by combining suspensions of washed platelets from affected GSDs in PPP from a control dog and washed platelets from a control dog in PPP from affected GSDs.Prothrombin consumption test We measured serum CT as an index of prothrombin consumption.36 Serum aliquots were collected after 1, 2, and 7 hours of incubation (at 37°C) and immediately combined with 3.2% sodium citrate (1 vol citrate: 9 vol serum). For the PT assay, the citrate serum was added to a bovine fibrinogen solution (Sigma) containing a final concentration of fibrinogen of 1.5 mg/mL. The time for clot formation was then measured after the addition of a thromboplastin and calcium reagent (Thromboplastin-L, Pacific Hemostasis). We compared each serum PT to the PT of a plasma sample drawn at the time of whole blood collection. The residual serum prothrombin was expressed as a serum PT ratio (serum PT % = plasma PT/serum PT × 100). In a series of mixing studies, we determined the residual serum PT for affected GSD blood combined with increasing proportions of normal dog blood (mixtures containing from 10% to 90% normal dog blood). We also measured the serum PT percentage of all available parents, grandparents, and littermates of the 5 affected dogs and all dogs in 3 litters sired by 1 of the affected dogs. Samples for these analyses were shipped frozen on dry ice to our laboratory and assayed within 3 days of collection.Platelet phospholipid composition We collected 12 mL of blood directly into acid citrate dextrose (ACD) (National Institutes of Health formula A: 1 vol ACD: 5 vol blood) from 2 affected GSDs and 2 control dogs and prepared PRP (as described above) except for the addition of 1 µM prostaglandin E1 (PGE1). The PGE1-treated PRP was centrifuged (21°C) at 16 000g for 20 seconds, and the resultant platelet pellets were washed twice in platelet wash buffer (113 mM NaCl, 4.3 mM K2HPO4, 4.2 mM Na2HPO4, 24.4 mM NaH2PO4, 5.5 mM glucose, 1 µM PGE1, pH 6.3).37 After the second wash, platelets were resuspended to a final concentration of 1 × 109 platelets per 1.0 mL wash buffer and recentrifuged. The supernatants were discarded, and the platelet pellets were frozen at 70°C until analysis. Platelet pellets were
prepared and analyzed from each dog on 2 different dates. Lipids from
each platelet pellet were chloroform-extracted38 and then
separated using a Shimadzu high-performance liquid
chromatography system (consisting of 2 Model LC-10A pumps, a Model
SIL-10A autosampler, system controller Model SCL-10A, and an SPD-10AV
UV detector, Columbia, MD). Bovine phospholipid standards,
L- -PI, L--PS, L--PE,
L--PC, and SM, were used at 10 mg/mL stock solutions
(Avanti Polar Lipids, Alabaster, AL). Phospholipid separation was
achieved on a stainless steel µ-Porasil 3.9 × 300 mm I.D. analytic
column (10 µ particle size, 125 Å pore size [Waters,
Milford, MA]). The mobile phase was acetonitrile:methanol:85% phosphoric acid (100:5:1.5). Analyses were performed in isocratic mode
at a flow rate of 1.0 mL/min and pressure of 40 kilogram-force/cm2. Detector wavelength was 203 nM, and the
system was washed between runs with 60 mL methanol and 25 mL
2-propanol. Major phospholipid classes were resolved within 23 minutes
in a single run. Retention times for PI, PS, PE, PC, and SM were 3.6, 5.9, 7.7, 11.7, and 20.1, respectively. The phospholipid concentrations
and peak-area values exhibited a linear relationship in the range of 0 to 8.0 µg/10µL of the standard mixtures. Phospholipid content (mole
percentage) was determined by peak-area integration (CLASS VP 4.2 software).
Platelet suspensions for determination of prothrombinase activity and flow cytometric analyses For these studies, PRP (3.2% citrate) was prepared as described above. After the addition of PGE1 (1 µM final), platelets were washed twice in platelet wash buffer and then resuspended to a final concentration of 25 × 109/L (2.5 × 107/mL) in resuspension buffer (137 mM NaCl, 4 mM KCl, 0.5 mM MgCl, 0.5 mM Na2HPO4, 0.1% glucose, 0.1% bovine serum albumin, and 10 mM HEPES, pH 7.4). Extracellular ionized calcium was adjusted to 2 mM by the addition of 1.5 M CaCl2, and platelets were equilibrated at room temperature for 30 minutes. Vehicle or agonist was then added to 1.0 mL aliquots of the platelet suspension in plastic tubes and gently mixed (Nutator, Becton Dickinson, Sparks, MD) at room temperature for 25 minutes. We tested pharmacologic and physiologic agonists previously shown to be inducers of membrane PS exposure and vesiculation:calcium ionophore (A23187 3 µM), thrombin (0.5 U/mL) collagen (24 µg/mL), and tetracaine (2 mM), a membrane-active agent that strongly induces PS exposure with only limited vesiculation.39Prothrombinase activity assay We measured platelet prothrombinase activity with minor modification of a previously reported method.40 Briefly, 0.25 U bovine factor Xa (Haematologic Technologies, Essex Junction, VT) was added to 1.0 mL unstimulated or agonist-treated platelets (2.5 × 107 cells in resuspension buffer containing 2 mM Ca++) followed by the immediate addition of 10 µg bovine prothrombin (Haematologic Technologies). At various times, 50 µL aliquots were removed and added to 550 µL stop buffer (0.15 M NaCl, 20 mM ethylenediaminetetraacetic acid, 5 mg/mL ovalbumin [Sigma], and 20 mM Tris-HCl, pH 7.9) to halt prothrombin conversion. Thrombin activity was measured by the addition of 50 µL thrombin substrate S-2238 (0.1 mM final, DiaPharma, West Chester, OH) to microtiter plate wells containing 200 µL sample or standard. Changes in absorbance values at 405 nM were recorded at 10-second intervals in the kinetic mode of an enzyme-linked immunosorbent assay plate reader (EL 312, BioTek Instruments, Winooski, VT) using the supplied Kinetic-Calc software. Thrombin concentration in each sample was determined from a calibration curve derived from purified bovine-thrombin (Haematologic Technologies).
Red blood cell prothrombinase activity assay We measured erythrocyte prothrombinase activity of 2 affected GSDs and 2 control dogs. For these studies, red cells were washed twice in platelet wash buffer, resuspended to a final concentration of 10 × 109/L in resuspension buffer containing 2 mM Ca++, and then reacted at 37°C with either 3 µM A23187 or a dimethyl sulfoxide vehicle control. The prothrombinase assay37 was configured with bovine prothrombin factors Va and Xa (Haematologic Technologies), and the nanomoles of thrombin generated per 107 red cells was measured as described above, after reaction times of 0, 30, 60, and 90 minutes.Flow cytometry We analyzed control and agonist-treated platelet suspensions from affected GSDs and healthy control dogs in a FACSCalibur cytometer (Becton Dickinson, San Jose, CA) using logarithmic gain settings for light scatter and fluorescence. Parameter settings were adjusted so that the cell population of PRP of each dog was centered on the second decade of the 4-decade log scales of the forward versus side light scatter dot plot. For each sample, 10 000 total events were acquired without gating. Forward and side scatter and fluorochrome binding were used to assess platelets and derived microparticles.39,41 PS exposure was detected by annexin V-fluorescein isothiocyanate (FITC) binding (TACS Annexin V-FITC, R&D Systems, Minneapolis, MN) and membrane surface glycoprotein (GP) IIIa by CD61-FITC binding (anti-CD61, clone Y2/51, Dako, Carpentieria, CA). In 100 µL reaction volumes, we labeled 10 µL aliquots of the platelet suspensions (containing 10 × 109/L [1 × 107/mL] platelets) using 0.1 µg CD61-FITC or isotype control antibody (mouse IgG1-FITC, clone DAK-GO1, Dako) or 0.0125 µg annexin V-FITC. After incubation in the dark for 30 minutes at 4°C (CD61-FITC and isotype control) or 15 minutes at room temperature (annexin V-FITC), 400 µL of suspension buffer was added to each reaction tube and the samples were analyzed within 30 minutes.Clot signature analysis We examined the platelet function and coagulant activity of flowing, nonanticoagulated whole blood using a point-of-care device (Clot Signature Analyzer, Xylum, Scarsdale, NY). Under conditions that simulate a small arterial bleeding site, the instrument displays tracings that represent shear-induced platelet activation with subsequent platelet plug formation and development of an occlusive fibrin clot.42 The clot signature analysis (CSA) tracings and numeric values of platelet-mediated hemostasis time (PHT) and CT of the 5 affected GSDs were compared with those of 6 healthy mixed breed dogs.
The results of coagulation, fibrinolysis, and VWF assays, platelet
count, and mean platelet volume determination were all within normal
limits (Table 1), as were mean plasma
cholesterol (6.00 mM/L; reference range 3.20 to 8.65) and mean plasma
triglyceride (0.54 mM/L; reference range 0.29 to 1.22). Under
light microscopy, affected GSD platelets appeared normal, and the GSDs
and control dogs had similar VWF multimer distribution and
hybridization intensities (data not shown). The 5 affected GSDs had
normal bleeding times, clot retraction, and platelet aggregation.
Platelet secretion response of the 3 affected GSDs studied was within
normal limits (Table 1).
Tests of platelet procoagulant activity All GSDs had long CTs in the PF3a assay. In mixing studies, CT was prolonged when the assay was configured with GSD platelets suspended in control dog plasma; however, CT was within normal limits when control dog platelets were suspended in GSD plasma (Table 2). Prothrombin times of GSD serum samples were nearly identical to their plasma PT. Consequently, serum PT ratio for these dogs was initially close to 100% and fell to only approximately 90% after 7 hours. In contrast, the mean serum PT ratio of 15 control dogs (including 5 healthy GSDs unrelated to the affected dogs) was less than 60% by 1 hour (Figure 2) and progressively fell at the 2-hour and 7-hour time points. The 1-hour serum PT ratio of mixtures combining whole blood from affected GSDs and control dogs fell to less than 60% only when the proportion of control dog blood was 75% or greater.
Platelet phospholipid composition The proportional phospholipid content of platelets from the affected GSDs and control dogs were similar (Table 3). In particular, the PS content of GSD platelets (11.1%) was nearly identical to that of control dogs (10.7%) and to a previously reported value of canine platelet PS content (11.8%).43
Platelet prothrombinase activity In our assay system, stirred unstimulated control dog platelets generated approximately 8 nM thrombin at 10 minutes' reaction time (Figure 3). A stimulated response was apparent in control platelets treated with calcium ionophore and the physiologic agonists thrombin and collagen. As previously reported for human platelets, ionophore induced maximal response, followed by combined thrombin plus collagen and then thrombin alone.39 In contrast, GSD platelets demonstrated minimal prothrombinase activity throughout a 10-minute reaction time, with indistinguishable values for unstimulated versus agonist-treated platelets (Figure 3). In preliminary experiments, the addition of 0.85 µg bovine factor Va to the reaction mixture failed to correct the lack of prothrombinase activity of the GSD platelets (data not shown).
Red cell prothrombinase activity The affected GSDs and control dogs had essentially identical red cell prothrombinase response. The prothrombinase activity of ionphore-treated control and GSD red cells increased over time, with a range of 44 to 74 nM thrombin per 107 cells at 30 minutes and 158 to 210 nM thrombin per 107 cells at 90 minutes. All ionophore-treated red cell suspensions (controls and GSDs) became hemolyzed over the 90-minute reaction time. Pending additional studies, we therefore cannot differentiate prothrombinase activity induced by ionophore-stimulated transbilayer PS movement from the nonspecific effects of red cell membrane rupture.Flow cytometry analyses Dot plots of unstimulated control dog and GSD platelet suspensions had similar size (assessed by forward scatter) and fluorescence intensity patterns. The presence of GPIIIa was evident by high-intensity labeling with CD61-FITC (Figure 4). In response to calcium ionophore stimulation (Figure 4C,D), the control dog platelet suspension showed a dramatic decrease in forward scatter. The CD61-FITC+ population now extended in an apparent continuum from the lower boundary of unstimulated platelets to the threshold of forward scatter detection. In contrast, the GSD platelet suspensions demonstrated a relatively small decrease in forward scatter for only a minor proportion of the CD61-FITC+ population. Annexin V did not bind to unstimulated control dog or GSD platelets (Figure 5A,B). Annexin V-FITC labeling of the ionophore-stimulated control dog platelet suspension (Figure 5C) showed dramatic decrease in forward scatter, with high-intensity fluorescence of this new population indicating the appearance of surface PS. The GSD suspensions showed almost no change in either forward scatter or fluorescence intensity in response to ionophore stimulation. When platelet suspensions were treated with thrombin plus collagen (Figure 5E,F), both control dogs and GSDs developed high-intensity-labeled annexin V-FITC subpopulations. However, fewer GSD platelets bound annexin V-FITC, and these platelets did not demonstrate the logfold decrease in forward scatter as did control platelets. The dot plots in response to tetracaine treatment (Figure 5G,H) were similar for control and GSD platelet suspensions, with essentially the entire population of platelets now demonstrating high-intensity labeling, denoting extensive surface PS exposure. Forward scatter of the major population of control and GSD platelets, however, did not decrease in response to tetracaine.
Clot signature analyses The control dog CSA tracings (Figure 6A) depicted a rapid return of pressure to baseline values as a platelet plug sealed the needle punch holes in the instrument tubing. A gradual drop in pressure followed as fibrin clot formation subsequently occluded the tubing lumen. Because no additions are made to the nonanticoagulated whole blood in this assay system, activated platelets are the primary source of phospholipid membrane for assembly of the coagulation factor complexes responsible for fibrin clot formation. The quantitative parameters PHT and CT were derived from 9 CSA evaluations of 6 healthy dogs. The mean PHT was 1.2 minutes (median 1.1 minute), and mean CT was 12 minutes (median 12.9 minutes). The CSA tracings of 15 determinations from the 5 affected GSDs demonstrated qualitatively normal platelet plug formation, with mean PHT of 1.8 minutes (median 1.2 minutes). The portion of the tracing representing fibrin clot formation was consistently abnormal for all GSDs, with CT of more than 30 minutes (the upper limit of instrument observation time). During this period, the GSD tracings demonstrated long intervals of sustained high pressure interrupted by one or more transient drops in pressure (Figure 6B).
Pedigree studies The serum PT ratio was used to evaluate platelet procoagulant activity of 3 GSD litters sired by 1 affected male (Figure 7). This male had been bred to 3 clinically normal females and produced a total of 22 offspring. All offspring in 2 of these litters had no signs of abnormal bleeding by 1.5 years of age and had serum PT ratios within a reference range of 21% to 62% (derived from 2-hour serum CTs of 25 healthy dogs). In the third litter, 3 of 9 pups had prolonged bleeding after surgery or minor trauma, and all 3 had marked elevation of their serum PT ratios (range 96%-104%). The dam of this litter when bred to a different, clinically normal male produced a litter consisting of 4 pups with no clinical signs and 2 pups that experienced abnormal bleeding.
Many hereditary hemostatic disorders have been identified in dogs. While canine hemophilia and von Willebrand disease are common, a variety of clotting factor deficiencies and platelet function defects caused by surface glycoprotein abnormalities, storage pool defects, and failure of signal transduction occur in this species.44-46 Comprehensive testing of the GSDs described in this report revealed a new canine hemostatic defect with features comparable to Scott syndrome of human beings. The affected dogs experienced a mild to moderate bleeding tendency but had normal in vitro coagulation and normal response to tests of platelet adhesion, aggregation, and secretion. In contrast, abnormal values were consistently found in all tests of platelet procoagulant activity. The association of a bleeding tendency with deficiency of platelet procoagulant activity, in both dogs and human beings, underscores the importance of this platelet response for supporting in vivo hemostasis. The presence of a bleeding disorder in this colony was evident through at least 5 generations. Although attempts were made to exclude affected dogs from the breeding program, many dogs subsequently confirmed as carriers and a few affected dogs were bred, thereby disseminating the defect throughout the closed colony. Based upon pedigree inspection and assessment of residual serum prothrombin (PT ratio), the hemostatic defect in this colony appears to be an autosomal recessive trait. Affected males and females have been identified in roughly equal numbers, with no obvious decrease in litter size or excess neonatal mortality in litters with affected pups. Obligate carrier males and females demonstrate normal residual serum prothrombin and no evidence of a bleeding tendency, even after surgery. Progeny tests of 3 litters sired by an affected male (bred to 3 different clinically normal females) produced 3 of 22 pups with high serum PT ratios and expression of a bleeding tendency. This proportion of affected pups is lower than expected for an autosomal dominant trait, assuming either homozygosity or heterozygosity of the affected male. Confirmation of autosomal recessive inheritance and expression will require evaluation of outcross and backcross litters and, ultimately, identification of the underlying molecular defect. The affected dogs' specific lack of platelet procoagulant activity appears to be caused by an intrinsic platelet defect. Washed platelets from affected GSDs do not support kaolin-activated clot formation when combined with normal dog plasma in the PF3a assay. In contrast, assays configured with control dog platelets and affected GSD plasma as source of clotting factors have normal PF3a. In a prothrombinase assay system, washed stimulated GSD platelets combined with an excess of activated bovine factors are unable to generate thrombin beyond the background levels of unstimulated platelets. This lack of prothrombinase activity cannot be attributed to membrane PS deficiency because GSD and control platelets have the same PS content. Furthermore, GSD platelets treated with tetracaine express surface PS in a similar manner as control platelets, as evidenced by their high-intensity labeling with an annexin V fluorescent probe. This normal response to tetracaine, a local anesthetic whose actions include direct exchange with membrane PS,47 contrasts with GSD platelets' abnormal membrane response to calcium ionophore and the physiologic platelet agonists thrombin and collagen. Flow cytometry dot plots of control dog platelets stimulated with ionophore A23187 exhibited the same qualitative changes described for human platelets, ie, annexin V binding and decreased forward light scatter.39 The decrease in forward scatter was pronounced, and the scatter plots consisted primarily of events with high prevalence surface GPIIIa and PS, denoting extensive platelet membrane microvesiculation.41 Ionophore treatment of GSD platelets induced virtually no PS exposure and only a minor shift in forward scatter of the GPIIIa+ events. This change in forward scatter is compatible with platelet shape change and granule release rather than microvesiculation.48,49 As described for human platelets,14,39 thrombin plus collagen stimulation induced PS exposure and microvesiculation in only a subpopulation of the control dog platelets. Some surface exposure of PS was also apparent in a subpopulation of the thrombin plus collagen-treated GSD platelets, in contrast to their lack of PS exposure in response to ionophore. The GSD suspensions, however, had relatively fewer platelets exposing surface PS and little evidence of microvesiculation, compatible with their failure to generate thrombin in the prothrombinase assay system. Collagen is a critical physiologic stimulus of platelet membrane PS exposure and microvesiculation.39,50,51 The collagen-evoked responses are mediated by sustained high [Ca++]i and are associated with activation of both protein tyrosine kinases and tyrosine phosphatases.52,53 Although the biochemical and molecular basis of Scott syndrome is unknown, transformed Scott lymphoblasts display defective capacitative Ca++ entry54 and Scott lymphoblasts, red cells, and platelets have abnormal patterns of protein tyrosine phosphorylation.22,54,55 The GSD platelets demonstrate normal aggregation and secretion in response to collagen, indicating that the collagen receptor, signal transduction, and effector pathways leading to release of intracellular Ca++ stores and platelet shape change are intact. Some of the thrombin plus collagen-stimulated GSD platelets appear to be capable of PS exposure, albeit with minimal evidence of vesiculation. In vitro, normal human platelets can be induced to expose membrane PS without vesiculation under reaction conditions that limit Ca++ influx, block activation of protein tyrosine phosphatases, or inhibit µ-calpain activity.14,52 Studies of these processes in GSD platelets are likely to help elucidate pathways that are unique to or predominate in the platelet membrane changes resulting in platelet procoagulant activity. In addition, the discovery of a canine model will allow application of candidate gene and mapping strategies to define a molecular defect capable of producing the characteristic Scott syndrome phenotype.
The authors thank Drs Harvey Weiss and Bruce Lages for their critical review and comments.
Submitted August 9, 2001; accepted November 16, 2001.
Supported in part by the National Institutes of Health (GM58516) and Sidney Kimmel Foundation for Cancer Research (H.A.B.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Marjory Brooks, Comparative Coagulation Section, Diagnostic Laboratory, Cornell University, Upper Tower Rd, Ithaca, NY 14853; e-mail: mbb9{at}cornell.edu.
1. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736:57-66[Medline] [Order article via Infotrieve]. 2. Zwaal RF, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta. 1992;1180:1-8[Medline] [Order article via Infotrieve]. 3. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol. 1992;29:213-226[Medline] [Order article via Infotrieve].
4.
Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ.
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.
J Biol Chem.
1989;264:17049-17057 5. Zwaal RF, Comfurius P, Bevers EM. Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem Soc Trans. 1993;21:248-253[Medline] [Order article via Infotrieve]. 6. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1999;1439:317-330[Medline] [Order article via Infotrieve].
7.
Seigneuret M, Devaux PF.
ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes.
Proc Natl Acad Sci U S A.
1984;81:3751-3755 8. Schroit AJ, Zwaal RF. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta. 1991;1071:313-329[Medline] [Order article via Infotrieve].
9.
Basse F, Stout JG, Sims PJ, Wiedmer T.
Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid.
J Biol Chem.
1996;271:17205-17210
10.
Zhou Q, Zhao J, Stout JG, et al.
Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids.
J Biol Chem.
1997;272:18240-18244 11. Dachary-Prigent J, Pasquet JM, Freyssinet JM, Nurden AT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Biochemistry. 1995;34:11625-11634[CrossRef][Medline] [Order article via Infotrieve].
12.
Zwaal RF, Schroit AJ.
Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.
Blood.
1997;89:1121-1132
13.
Solum NO.
Procoagulant expression in platelets and defects leading to clinical disorders.
Arterioscler Thromb Vasc Biol.
1999;19:2841-2846 14. Pasquet JM, Dachary-Prigent J, Nurden AT. Microvesicle release is associated with extensive protein tyrosine dephosphorylation in platelets stimulated by A23187 or a mixture of thrombin and collagen. Biochem J. 1998;333:591-599. 15. Goodwin CA, Wheeler-Jones CP, Kakkar VV, et al. Thrombin receptor activating peptide does not stimulate platelet procoagulant activity. Biochem Biophys Res Commun. 1994;202:321-327[CrossRef][Medline] [Order article via Infotrieve]. 16. Briede JJ, Heemskerk JW, Hemker HC, Lindhout T. Heterogeneity in microparticle formation and exposure of anionic phospholipids at the plasma membrane of single adherent platelets. Biochim Biophys Acta. 1999;1451:163-172[Medline] [Order article via Infotrieve].
17.
Andersen H, Greenberg DL, Fujikawa K, et al.
Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity.
Proc Natl Acad Sci U S A.
1999;96:11189-11193
18.
Beguin S, Kumar R, Keularts I, et al.
Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor.
Blood.
1999;93:564-570 19. Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol. 1994;31:312-319[Medline] [Order article via Infotrieve].
20.
Weiss HJ, Lages B.
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity
21.
Bevers EM, Wiedmer T, Comfurius P, et al.
The complex of phosphatidylinositol 4,5-bisphosphate and calcium ions is not responsible for Ca(2+)-induced loss of phospholipid asymmetry in the human erythrocyte: a study in Scott syndrome, a disorder of calcium-induced phospholipid scrambling.
Blood.
1995;86:1983-1991 22. Dachary-Prigent J, Pasquet JM, Fressinaud E, et al. Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics. Br J Haematol. 1997;99:959-967[CrossRef][Medline] [Order article via Infotrieve]. 23. Weiss HJ, Vicic WJ, Lages BA, Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med. 1979;67:206-213[CrossRef][Medline] [Order article via Infotrieve].
24.
Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM.
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder.
Blood.
1996;87:1409-1415 25. Janel N, Leroy C, Laude I, et al. Assessment of the expression of candidate human plasma membrane phospholipid scramblase in Scott syndrome cells [letter]. Thromb Haemost. 1999;81:322-323[Medline] [Order article via Infotrieve].
26.
Zhou Q, Sims PJ, Wiedmer T.
Expression of proteins controlling transbilayer movement of plasma membrane phospholipids in the B lymphocytes from a patient with Scott syndrome.
Blood.
1998;92:1707-1712 27. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63[CrossRef][Medline] [Order article via Infotrieve]. 28. Byars TD, Ling GV, Ferris NA, Keeton KS. Activated coagulation time (ACT) of whole blood in normal dogs. Am J Vet Res. 1976;37:1359-1361[Medline] [Order article via Infotrieve]. 29. Benson RE, Catalfamo JL, Brooks MB, Dodds WJ. A sensitive immunoassay for von Willebrand factor. J Immunoassay. 1991;12:371-390[Medline] [Order article via Infotrieve]. 30. Brosstad F, Kjonniksen I, Ronning B, Stormorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost. 1986;55:276-278[Medline] [Order article via Infotrieve]. 31. Brooks MB, Erb HN, Foureman PA, Ray K. von Willebrand disease phenotype and von Willebrand factor marker genotype in Doberman Pinschers. Am J Vet Res. 2001;62:364-369[CrossRef][Medline] [Order article via Infotrieve]. 32. Lanevschi A, Kramer JW, Greene SA, Meyers KM. Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs. Am J Vet Res. 1996;57:1124-1130[Medline] [Order article via Infotrieve]. 33. Brooks M, Catalfamo J. Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders. Thromb Haemost. 1993;70:777-780[Medline] [Order article via Infotrieve].
34.
Catalfamo JL, Raymond SL, White JG, Dodds WJ.
Defective platelet-fibrinogen interaction in hereditary canine thrombopathia.
Blood.
1986;67:1568-1577 35. Callan MB, Shofer FS, Wojenski C, Giger U. Chrono-lume and magnesium potentiate aggregation of canine but not human platelets in citrated platelet-rich plasma. Thromb Haemost. 1998;80:176-180[Medline] [Order article via Infotrieve]. 36. Castaman G, Yu-Feng L, Battistin E, Rodeghiero F. Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation. Br J Haematol. 1997;96:458-463[CrossRef][Medline] [Order article via Infotrieve].
37.
Thiagarajan P, Tait JF.
Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles.
J Biol Chem.
1991;266:24302-24307 38. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
39.
Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT.
Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups.
Blood.
1993;81:2554-2565
40.
Dormann D, Clementson KJ, Kehrel BE.
The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity.
Blood.
2000;96:2469-2478 41. Bode AP, Hickerson DH. Characterization and quantitation by flow cytometry of membranous microparticles formed during activation of platelet suspensions with ionophore or thrombin. Platelets. 2000;11:259-271[CrossRef][Medline] [Order article via Infotrieve]. 42. Li CK, Hoffmann TJ, Hsieh PY, Malik S, Watson WC. The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury. Thromb Res. 1998;92:S67-S77[CrossRef][Medline] [Order article via Infotrieve]. 43. Pitas RE, Nelson GJ, Jaffe RM, Mahley RW. Effects of diets high in saturated fat and cholesterol on the lipid composition of canine platelets. Lipids. 1979;14:469-477[CrossRef][Medline] [Order article via Infotrieve].
44.
Brooks MB.
A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection.
J Hered.
1999;90:112-118 45. Denis CV, Wagner DD. Insights from von Willebrand disease animal models. Cell Mol Life Sci. 1999;56:977-990[CrossRef][Medline] [Order article via Infotrieve]. 46. Catalfamo JL, Dodds WJ. Thrombopathias. In: Feldman BF,Zinkl JG,Jain NC, eds. Schalm's Veterinary Hematology. 5th ed. Philadelphia, PA: Lippincott Williams Wilkins; 2000:1042-1050. 47. Kelusky EC, Boulanger Y, Schreier S, Smith IC. A 2H-NMR study on the interactions of the local anesthetic tetracaine with membranes containing phosphatidylserine. Biochim Biophys Acta. 1986;856:85-90[Medline] [Order article via Infotrieve]. 48. Latimer P, Born GV, Michal F. Application of light-scattering theory to the optical effects associated with the morphology of blood platelets. Arch Biochem Biophys. 1977;180:151-159[CrossRef][Medline] [Order article via Infotrieve]. 49. Stuart MC, Bevers EM, Comfurius P, et al. Ultrastructural detection of surface exposed phosphatidylserine on activated blood platelets. Thromb Haemost. 1995;74:1145-1151[Medline] [Order article via Infotrieve]. 50. Bevers EM, Karniguian A, Legrand YJ, Zwaal RF. Collagen derived octapeptide inhibits platelet procoagulant activity induced by the combined action of collagen and thrombin. Thromb Res. 1985;37:365-370[CrossRef][Medline] [Order article via Infotrieve].
51.
Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T.
Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses.
Blood.
1997;90:2615-2625 52. Pasquet JM, Dachary-Prigent J, Nurden AT. Comparison between the loss of platelet membrane asymmetry, microvesiculation and the tyrosine phosphorylation of proteins. Prostaglandins Leukot Essent Fatty Acids. 1997;57:451-453[CrossRef][Medline] [Order article via Infotrieve]. 53. Heemskerk JW, Siljander PR, Bevers EM, Farndale RW, Lindhout T. Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets. 2000;11:301-306[CrossRef][Medline] [Order article via Infotrieve]. 54. Martinez MC, Martin S, Toti F, et al. Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells. Biochemistry. 1999;38:10092-10098[CrossRef][Medline] [Order article via Infotrieve].
55.
Dekkers DW, Comfurius P, Vuist WM, et al.
Impaired Ca2+-induced tyrosine phosphorylation and defective lipid scrambling in erythrocytes from a patient with Scott syndrome: a study using an inhibitor for scramblase that mimics the defect in Scott syndrome.
Blood.
1998;91:2133-2138
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  N. B. Norgard, C. L. Hann, and G. L. Dale Cangrelor Attenuates Coated-Platelet Formation Clinical and Applied Thrombosis/Hemostasis, April 1, 2009; 15(2): 177 - 182. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Monroe, M. Hoffman, and H. R. Roberts Platelets and Thrombin Generation Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1381 - 1389. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
3 subunit of
GPIIb/IIIa. Unstimulated platelet suspensions (A,B) and calcium
ionophore-treated suspensions (C,D) were stirred in a buffer
containing 2 mM CaCl2 in the absence or presence of 3 µM
A23187. Control and GSD platelets demonstrate high-intensity labeling;
however, only control platelets developed a marked decrease in forward
scatter in response to ionophore treatment. Arrows indicate increasing
forward light scatter intensity and increasing green fluourescence
intensity. Data were collected without gating. The horizontal quadrant
marker is set at the lower boundary of forward scatter for unstimulated
platelets, and the vertical marker is set at the upper boundary of
fluorescence for 95% of the isotype control-labeled particles
(indicating nonspecific fluorescence). Particles in the lower left
quadrant of each plot represent debris and machine noise. These plots
correspond to a single analysis, representative of results obtained
from ionophore treatment of all 5 affected GSDs.
